Orofar 1 mg/1 mg lozenges България - български - Изпълнителна агенция по лекарствата

orofar 1 mg/1 mg lozenges

novartis consumer health gmbh - различни - 1 mg/1 mg lozenges

Orofar 0,2%/0,15% oromuconasal spray, Solution България - български - Изпълнителна агенция по лекарствата

orofar 0,2%/0,15% oromuconasal spray, solution

novartis consumer health gmbh - Лидокаин, хлорид Бензалкония - 0,2%/0,15% oromuconasal spray, solution

Orofar Intense 8,75 mg/dose oromucosal spray, solution България - български - Изпълнителна агенция по лекарствата

orofar intense 8,75 mg/dose oromucosal spray, solution

8,75 mg/dose oromucosal spray, solution

PAROFOR 140 mg/ml solution for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs 200 mg/ml България - български - БАБХ (Българска агенция по безопасност на храните)

parofor 140 mg/ml solution for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs 200 mg/ml

huvepharma nv - Сулфат паромомицин - разтвор за прилагане във водата за пиене/млако или млекозаместител - 200 mg/ml - говеда, прасета

PAROFOR 70 000 IU/g powder for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs 100 mg/g България - български - БАБХ (Българска агенция по безопасност на храните)

parofor 70 000 iu/g powder for use in drinking water, milk or milk replacer for pre-ruminant cattle and pigs 100 mg/g

huvepharma nv - Сулфат паромомицин - прах за прилагане във вода за пиене - 100 mg/g - прасета, телета

PAROFOR crypto 140 000 IU/ml oral solution for pre-ruminant cattle 140 000 IU/ml България - български - БАБХ (Българска агенция по безопасност на храните)

parofor crypto 140 000 iu/ml oral solution for pre-ruminant cattle 140 000 iu/ml

huvepharma nv - Паромомицин - перорален разтвор - 140 000 iu/ml - телета

PAROFOR crypto 140 000 IU/ml oral solution for sheep and goats 140 000 IU/ml България - български - БАБХ (Българска агенция по безопасност на храните)

parofor crypto 140 000 iu/ml oral solution for sheep and goats 140 000 iu/ml

huvepharma nv - Паромомицин - перорален разтвор - 140 000 iu/ml - кози, овце

Plavix Европейски съюз - български - EMA (European Medicines Agency)

plavix

sanofi winthrop industrie - клопидогрел хидрогенсулфат - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - Антитромботични агенти - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. Предотвратяване на атеротромботических и тромбоемболични събития при предсърдно fibrillationin възрастни пациенти с фибрилляцией мъждене, които имат поне един рисков фактор за развитие на съдови събития, не са подходящи за лечение на витамин К-антагонисти и които имат по-нисък риск от кървене, клопидогрел е показан в комбинация с ВЪЗХОДЯЩО за профилактика атеротромботических и тромбоемболични събития, включително инсулт.

Clopidogrel Acino Европейски съюз - български - EMA (European Medicines Agency)

clopidogrel acino

acino ag - клопидогрел - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - Антитромботични агенти - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Европейски съюз - български - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - клопидогрел хидрохлорид - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Антитромботични агенти - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.